Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer's Disease: Advances and Future Directions - PubMed
3 months ago
- #Alzheimer's disease
- #Amyloid beta aggregation
- #Nanomedicine
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia in the elderly.
- Amyloid beta (Aβ) aggregation and neuroinflammation are central and interlinked mechanisms driving AD progression.
- Natural products like curcumin, resveratrol, Ginkgo biloba, EGCG, crocin, ashwagandha, and CBD show promise in modulating Aβ aggregation and neuroinflammation.
- Therapeutic application of these natural products is limited by poor solubility, instability, rapid metabolism, and low BBB permeability.
- Nanotechnology-based drug delivery systems (e.g., polymeric nanoparticles, niosomes, solid lipid nanoparticles) enhance brain targeting and bioavailability.
- This review highlights the potential of natural compounds and nanocarriers in developing future disease-modifying AD therapies.